Skip to content

News & Media

20th March 2024
NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy
13th March 2024
Treatment Advances In Telomere Biology Disorders
8th March 2024
What strategies are being employed to accelerate product development and commercialization without compromising quality?
8th March 2024
What strategies are being employed to accelerate product development and commercialization without compromising quality?
4th March 2024
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
30th January 2024
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
14th December 2023
What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?
1st December 2023
Managing Raw Material Variability for Autologous Cell Therapies
16th October 2023
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
11th October 2023
A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine EXG-5003 against SARS-CoV-2
Top